Brewin Dolphin LTD Iovance Biotherapeutics, Inc. Transaction History

Brewin Dolphin LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Nov 09, 2023	SELL	$28.67 - $52.59 $8,457 - $15,514	-295 Closed	0 $0
Q2 2020 Nov 09, 2023	SELL	$27.21 - $41.0 $194,687 - $293,355	-7,155 Reduced 96.04%	295 $8.1 Million
Q1 2020 Nov 09, 2023	SELL	$19.54 - $38.85 $104,929 - $208,624	-5,370 Reduced 41.89%	7,450 $223 Million
Q4 2019 Nov 09, 2023	BUY	$17.95 - $29.41 $137,586 - $225,427	7,665 Added 148.69%	12,820 $355 Million
Q3 2019 Nov 09, 2023	SELL	$17.99 - $26.0 $38,138 - $55,120	-2,120 Reduced 29.14%	5,155 $93.8 Million
Q2 2019 Nov 09, 2023	BUY	$9.78 - $24.52 $20,733 - $51,982	2,120 Added 41.13%	7,275 $178 Million
Q2 2018 Nov 09, 2023	BUY	$12.45 - $16.95 $64,179 - $87,377	5,155 New	5,155 $66 Million

316

244M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $898M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

Stay updated on Brewin Dolphin LTD with notifications on news.